

Biju George

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7108143/publications.pdf>

Version: 2024-02-01

260
papers

3,214
citations

185998

28
h-index

205818

48
g-index

265
all docs

265
docs citations

265
times ranked

3986
citing authors

#	ARTICLE	IF	CITATIONS
1	Disease Status at Transplant has a Significant Impact on Outcomes of Autologous Transplantation (ASCT) in Patients with Hodgkin Lymphoma—A Single Center Experience. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2022, 38, 290-298.	0.3	1
2	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 339-357.	2.5	35
3	Impact of donor telomere length on survival in patients undergoing matched sibling donor transplantation for aplastic anaemia. <i>British Journal of Haematology</i> , 2022, 196, 724-734.	1.2	2
4	Haploidentical transplantation is feasible and associated with reasonable outcomes despite major infective complications—A single center experience from India. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 45.e1-45.e8.	0.6	6
5	Outcomes of patients with hematologic malignancies and COVID-19 from the Hematologic Cancer Registry of India. <i>Blood Cancer Journal</i> , 2022, 12, 2.	2.8	7
6	Effectiveness of a real-time PCR for diagnosis of <i>Pneumocystis pneumonia</i> in immunocompromised patients—Experience from a tertiary care center, India. <i>Journal De Mycologie Medicale</i> , 2022, 32, 101241.	0.7	2
7	Real world data with concurrent retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia. <i>Blood Cancer Journal</i> , 2022, 12, 22.	2.8	8
8	Draft genome sequences data of rare <i>Salmonella enterica</i> sub sp. <i>enterica</i> serovar Ceyco and serovar Hillegersberg isolated from diarrheal patients in India. <i>Data in Brief</i> , 2022, 41, 107875.	0.5	1
9	BK polyomavirus hemorrhagic cystitis in hematopoietic cell transplant recipients. <i>Journal of Global Infectious Diseases</i> , 2022, 14, 17.	0.2	6
10	ALK-positive large B-cell lymphomas: A clinicopathologic study.. <i>Indian Journal of Pathology and Microbiology</i> , 2022, 65, 381-386.	0.1	1
11	Hybrid Plasmids Encoding Antimicrobial Resistance and Virulence Traits Among Hypervirulent <i>Klebsiella pneumoniae</i> ST2096 in India. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 875116.	1.8	15
12	Endothelial Activation and Stress Index-Measured Pretransplantation Predicts Transplantation-Related Mortality in Patients with Thalassemia Major Undergoing Transplantation with Thiotepe, Treosulfan, and Fludarabine Conditioning. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 356.e1-356.e6.	0.6	2
13	Single Dose of Ivermectin is not Useful in Patients with Hematological Disorders and COVID-19 Illness: A Phase II B Open Labelled Randomized Controlled Trial. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2022, 38, 615-622.	0.3	4
14	In utero origin of myelofibrosis presenting in adult monozygotic twins. <i>Nature Medicine</i> , 2022, 28, 1207-1211.	15.2	26
15	Novel frameshift variant (c.409dupG) in <i>SLC25A38</i> is a common cause of congenital sideroblastic anaemia in the Indian subcontinent. <i>Journal of Clinical Pathology</i> , 2021, 74, 157-162.	1.0	3
16	Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 68.e1-68.e9.	0.6	15
17	Safety of peripheral blood stem cell harvest in children under anaesthesia in the day care setting—A single centre experience. <i>Transfusion and Apheresis Science</i> , 2021, 60, 102962.	0.5	1
18	Primary Immunodeficiencies in India: Molecular Diagnosis and the Role of Next-Generation Sequencing. <i>Journal of Clinical Immunology</i> , 2021, 41, 393-413.	2.0	17

#	ARTICLE	IF	CITATIONS
19	Management of relapse in acute promyelocytic leukaemia treated with upâ€front arsenic trioxideâ€based regimens. <i>British Journal of Haematology</i> , 2021, 192, 292-299.	1.2	13
20	Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis. <i>Blood</i> , 2021, 137, 556-568.	0.6	34
21	Sitosterolemia: Four Cases of an Uncommon Cause of Hemolytic Anemia (Mediterranean) <i>Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf</i> 2021, 37, 157-161.	0.3	2
22	A study to compare Hematopoietic Progenitor Cell count determined on a nextâ€generation automated cell counter with flow cytometric CD34 count in peripheral blood and the harvested peripheral blood stem cell graft from autologous and allogeneic donors. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 76-83.	0.7	5
23	Outcome of iron reduction therapy in ex-thalassemics. <i>PLoS ONE</i> , 2021, 16, e0238793.	1.1	3
24	Infections in Hematopoietic Stem Cell Transplantation (HSCT) Patients. <i>Organ and Tissue Transplantation</i> , 2021, , 545-560.	0.0	0
25	Monoclonal Gammopathies of â€Neurological Significanceâ€™: Paraproteinemic Neuropathies. <i>Canadian Journal of Neurological Sciences</i> , 2021, 48, 616-625.	0.3	5
26	Clinical, Immunological, and Molecular Profile of Chronic Granulomatous Disease: A Multi-Centric Study of 236 Patients From India. <i>Frontiers in Immunology</i> , 2021, 12, 625320.	2.2	31
27	Clinical and Molecular Findings in Mendelian Susceptibility to Mycobacterial Diseases: Experience From India. <i>Frontiers in Immunology</i> , 2021, 12, 631298.	2.2	36
28	How I treat immune thrombocytopenia â€ a global view. <i>British Journal of Haematology</i> , 2021, 193, 1076-1086.	1.2	4
29	Spectrum of Systemic Auto-Inflammatory Diseases in India: A Multi-Centric Experience. <i>Frontiers in Immunology</i> , 2021, 12, 630691.	2.2	11
30	Outcomes in adolescent and young adult acute lymphoblastic leukaemia: a report from the Indian Acute Leukaemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC). <i>British Journal of Haematology</i> , 2021, 193, e1-e4.	1.2	9
31	Mutation profile in BCR-ABL1-negative myeloproliferative neoplasms: A single-center experience from India. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, , .	0.6	2
32	Systematic application of fluorescence in situ hybridization and immunophenotype profile for the identification of ZNF384 gene rearrangements in B cell acute lymphoblastic leukemia. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 658-663.	0.7	5
33	An Antithymocyte Globulin-Free Conditioning Regimen Using Fludarabine and Cyclophosphamide Is Associated with Good Outcomes in Patients Undergoing Matched Related Family Donor Transplantation for Aplastic Anemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 409.e1-409.e6.	0.6	7
34	An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 3068-3077.	1.3	13
35	NUDT15 c.415C>T Polymorphism Predicts 6-MP Induced Early Myelotoxicity in Patients with Acute Lymphoblastic Leukemia Undergoing Maintenance Therapy. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 1303-1313.	0.4	0
36	Real World Data of Concurrent Arsenic Trioxide and All-Trans Retinoic Acid with Minimal Use of Anthracycline in the Treatment of Acute Promyelocytic Leukemia. <i>Blood</i> , 2021, 138, 2338-2338.	0.6	1

#	ARTICLE	IF	CITATIONS
37	Germline Variants Contribute Significantly to the Pathogenesis of Aplastic Anemia in India. <i>Blood</i> , 2021, 138, 1105-1105.	0.6	0
38	Covid-19 Infection in Hematological Malignancies: Registry Data from India. <i>Blood</i> , 2021, 138, 1938-1938.	0.6	0
39	Dysregulated Neutrophil Iron Homeostasis in β^2 -Thalassemia Impairs Phagocytosis and Reactive Oxygen Species Production. <i>Blood</i> , 2021, 138, 942-942.	0.6	1
40	Endothelial Activation and Stress Index (EASIX) Measured Pre-Transplant Identifies a Subgroup with High Transplant Related Mortality in Patients with Thalassemia Undergoing Stem Cell Transplantation Using Thiotepa-Treosulfan-Fludarabine Conditioning. <i>Blood</i> , 2021, 138, 1781-1781.	0.6	0
41	Haploidentical Natural Killer Cell Therapy As an Adjunct to Stem Cell Transplantation for Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 3827-3827.	0.6	1
42	Combining Arsenic Trioxide and Mitocans Selectively Disrupts Cellular Energetics in Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 2245-2245.	0.6	0
43	Optimization of Robust Diagnostic Strategy for Patients with Fanconi Anaemia (FA)- an Indian Perspective. <i>Blood</i> , 2021, 138, 2187-2187.	0.6	0
44	Molecular Characterization of G6PD Deficiency: Report of Three Novel G6PD Variants. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2020, 36, 349-355.	0.3	14
45	Endocrine Challenges and Metabolic Profile in Recipients of Allogeneic Haematopoietic Stem Cell Transplant: A Cross-Sectional Study from Southern India. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2020, 36, 484-490.	0.3	1
46	Pharmacokinetics and Efficacy of Generic Melphalan Is Comparable to Innovator Formulation in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 130-135.e1.	0.2	2
47	Comparison of the Efficacy of Innovator Rituximab and its Biosimilars in Diffuse Large B Cell Lymphoma Patients: A Retrospective Analysis. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2020, 36, 71-77.	0.3	7
48	A Prospective Observational Multi-institutional Study on Invasive Fungal Infections Following Chemotherapy for Acute Myeloid Leukemia (MISFIC Study): A Real World Scenario from India. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2020, 36, 97-103.	0.3	4
49	Do Bone Density, Bone Microarchitecture, and Body Composition Differ in Recipients of Allogeneic Hematopoietic Stem Cell Transplant? A Cross-Sectional Study from Southern India. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 540-545.	2.0	2
50	Screening of genetic variants in ELANE mutation negative congenital neutropenia by next generation sequencing. <i>Journal of Clinical Pathology</i> , 2020, 73, 322-327.	1.0	1
51	Impact of imaging modality on clinical outcome in Hodgkin lymphoma in a resource constraint setting. <i>British Journal of Haematology</i> , 2020, 188, 930-934.	1.2	2
52	Resource utilization and cost effectiveness of treating acute promyelocytic leukaemia using generic arsenic trioxide. <i>British Journal of Haematology</i> , 2020, 189, 269-278.	1.2	4
53	Comparison of outcomes of HCT in blast phase of <i>t(9;22)(q34;q11) BCR-ABL1</i> MPN with de novo AML and with AML following MDS. <i>Blood Advances</i> , 2020, 4, 4748-4757.	2.5	14
54	A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2139-2146.	2.0	14

#	ARTICLE	IF	CITATIONS
55	Prognostic value of MRD monitoring based on <i>BCR-ABL1</i> copy numbers in Philadelphia chromosome positive acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 3468-3475.	0.6	4
56	Prognostic plasma biomarkers of early complications and graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell transplantation. <i>EJHaem</i> , 2020, 1, 219-229.	0.4	10
57	Plasma imatinib levels and ABCB1 polymorphism influences early molecular response and failure-free survival in newly diagnosed chronic phase CML patients. <i>Scientific Reports</i> , 2020, 10, 20640.	1.6	9
58	Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. <i>Blood Advances</i> , 2020, 4, 2084-2094.	2.5	14
59	Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. <i>Haematologica</i> , 2020, 105, 1329-1338.	1.7	23
60	A Novel PDGFR β Rearrangement in Systemic Mastocytosis with an Associated Haematologic Neoplasm. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2020, 36, 773-775.	0.3	0
61	The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1137-1143.	2.0	13
62	Drug-resistant organisms are common in fecal surveillance cultures, predict bacteremia and correlate with poorer outcomes in patients undergoing allogeneic stem cell transplants. <i>Transplant Infectious Disease</i> , 2020, 22, e13273.	0.7	11
63	A phase II study evaluating the role of bortezomib in the management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide. <i>Cancer Medicine</i> , 2020, 9, 2603-2610.	1.3	14
64	Combination Lenalidomide/Bortezomib Treatment Synergistically Induces Calpain-Dependent Ikaros Cleavage and Apoptosis in Myeloma Cells. <i>Molecular Cancer Research</i> , 2020, 18, 529-536.	1.5	10
65	JAK2 exon 12 mutations in cases with JAK2V617F-negative polycythemia vera and primary myelofibrosis. <i>Annals of Hematology</i> , 2020, 99, 983-989.	0.8	10
66	Multicenter Outcome of Hematopoietic Stem Cell Transplantation for Primary Immune Deficiency Disorders in India. <i>Frontiers in Immunology</i> , 2020, 11, 606930.	2.2	10
67	Clinical, Immunological, and Molecular Features of Severe Combined Immune Deficiency: A Multi-Institutional Experience From India. <i>Frontiers in Immunology</i> , 2020, 11, 619146.	2.2	31
68	NUDT15 polymorphism explains serious toxicity to azathioprine in Indian patients with chronic immune thrombocytopenia and autoimmune hemolytic anemia: a case series. <i>Drug Metabolism and Personalized Therapy</i> , 2020, 35, .	0.3	9
69	Infections in Hematopoietic Stem Cell Transplantation (HSCT) Patients. <i>Organ and Tissue Transplantation</i> , 2020, , 1-18.	0.0	0
70	Ehl Factors at Lower Than Standard Dose Achieve Satisfactory Surgical Haemostasis in Haemophilia. <i>Blood</i> , 2020, 136, 25-26.	0.6	0
71	Clinical Outcomes in Multiple Myeloma Post-Autologous Transplantation—A Single Centre Experience. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2019, 35, 215-222.	0.3	10
72	Outcomes Following Allogeneic Stem Cell Transplantation Using Non-sibling Family Donors. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2019, 35, 43-49.	0.3	4

#	ARTICLE	IF	CITATIONS
73	Stromal cells downregulate miR-23a-5p to activate protective autophagy in acute myeloid leukemia. <i>Cell Death and Disease</i> , 2019, 10, 736.	2.7	31
74	Mucormycosis – A clinicoepidemiological review of cases over 10 years. <i>Mycoses</i> , 2019, 62, 391-398.	1.8	47
75	Pulmonary Complications in Pediatric and Adolescent Patients Following Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2024-2030.	2.0	33
76	Survival Trends in Infants Undergoing Allogeneic Hematopoietic Cell Transplant. <i>JAMA Pediatrics</i> , 2019, 173, e190081.	3.3	14
77	Will Ceftazidime/Avibactam Plus Aztreonam be Effective for NDM and OXA-48-Like Producing Organisms: Lessons Learnt from In vitro Study. <i>Indian Journal of Medical Microbiology</i> , 2019, 37, 34-41.	0.3	15
78	The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. <i>Blood Advances</i> , 2019, 3, 670-680.	2.5	71
79	Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. <i>Blood Advances</i> , 2019, 3, 3123-3131.	2.5	37
80	Related and unrelated donor transplantation for β^2 -thalassemia major: results of an international survey. <i>Blood Advances</i> , 2019, 3, 2562-2570.	2.5	48
81	Prevalence of FVIII inhibitors in severe haemophilia A patients: Effect of treatment and genetic factors in an Indian population. <i>Haemophilia</i> , 2019, 25, 67-74.	1.0	9
82	Heterogeneity of Mesenchymal Stromal Cells in Myelodysplastic Syndrome-with Multilineage Dysplasia (MDS-MLD). <i>Indian Journal of Hematology and Blood Transfusion</i> , 2019, 35, 223-232.	0.3	5
83	Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 362-368.	2.0	40
84	Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Versus Matched Unrelated Donor. <i>Blood</i> , 2019, 134, 3323-3323.	0.6	2
85	Outcomes in Adolescent and Young Adult (AYA) Acute Lymphoblastic Leukemia (ALL): A Report from the Indian Acute Leukemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC). <i>Blood</i> , 2019, 134, 1306-1306.	0.6	6
86	Induction Related Mortality in Acute Myeloid Leukemia: Multivariate Model of Predictive Score from the Indian Acute Leukemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC). <i>Blood</i> , 2019, 134, 2615-2615.	0.6	13
87	Safety of pediatric peripheral blood stem cell harvest in daycare setting: An institutional experience. <i>Anesthesia: Essays and Researches</i> , 2019, 13, 91.	0.2	1
88	Concerns with regard to an article. <i>Indian Journal of Medical Ethics</i> , 2019, 4, 251-251.	0.2	0
89	Fludarabine and Cyclophosphamide Based Conditioning Is Associated with Good Outcomes in Patients Undergoing Matched Sibling Donor Transplants for Aplastic Anaemia. <i>Blood</i> , 2019, 134, 3272-3272.	0.6	1
90	Targeting Extracellular Vesicle Secretion As a Strategy to Overcome Microenvironment Mediated Drug Resistance in Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 3733-3733.	0.6	1

#	ARTICLE	IF	CITATIONS
91	Impact of Graft Versus Host Disease on Outcome of Allogeneic Haematopoietic Stem Cell Transplantation for Thalassemia Major - Comparison of Bone Marrow Vs Peripheral Blood Stem Cell Grafts. <i>Blood</i> , 2019, 134, 4537-4537.	0.6	0
92	Treosulfan Metabolite (S, S-EBDM) Pharmacokinetics Influences Regimen Related Toxicity in Patients with Beta Thalassemia Major Undergoing HSCT. <i>Blood</i> , 2019, 134, 1977-1977.	0.6	0
93	Pharmacokinetics and Pharmacodynamics of Treosulfan in Patients With Thalassemia Major Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 575-583.	2.3	22
94	Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1928-1935.	2.0	2
95	Post stem cell transplantation revaccination: A survey of the current practices in India. <i>Vaccine</i> , 2018, 36, 2176-2180.	1.7	8
96	Second Hematopoietic Stem Cell Transplant for Thalassemia Major: Improved Clinical Outcomes with a Treosulfan-Based Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 103-108.	2.0	9
97	Post-Transplant Cyclophosphamide as Sole Graft-versus-Host Disease Prophylaxis Is Feasible in Patients Undergoing Peripheral Blood Stem Cell Transplantation for Severe Aplastic Anemia Using Matched Sibling Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 494-500.	2.0	22
98	Adult Acute Lymphoblastic Leukemia: Limitations of Intensification of Therapy in a Developing Country. <i>Journal of Global Oncology</i> , 2018, 4, 1-12.	0.5	12
99	Performance of an In-House Real-Time PCR Assay for Detecting Cytomegalovirus Infection among Transplant Patients from a Tertiary Care Centre. <i>Indian Journal of Medical Microbiology</i> , 2018, 36, 241-246.	0.3	4
100	Spectrum of ELANE mutations in congenital neutropenia: a single-centre study in patients of Indian origin. <i>Journal of Clinical Pathology</i> , 2018, 71, 1046-1050.	1.0	8
101	Arsenic Trioxide Enhances the NK Cell Cytotoxicity Against Acute Promyelocytic Leukemia While Simultaneously Inhibiting Its Bio-Genesis. <i>Frontiers in Immunology</i> , 2018, 9, 1357.	2.2	14
102	A Low Incidence of Cytomegalo Virus Infection Following Allogeneic Hematopoietic Stem Cell Transplantation Despite a High Seroprevalence. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2018, 34, 636-642.	0.3	6
103	Use of Non-Cryopreserved Peripheral Blood Stem Cells Is Associated with Adequate Engraftment in Patients with Multiple Myeloma Undergoing an Autologous Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, e31-e35.	2.0	18
104	Related and Unrelated Donor Transplantation for β^2 Thalassemia Major: Results of an International Survey. <i>Blood</i> , 2018, 132, 308-308.	0.6	1
105	Very Long Term Follow-up Data of Pediatric Acute Promyelocytic Leukemia Treated with Upfront Arsenic-Trioxide Based Regimens. <i>Blood</i> , 2018, 132, 1400-1400.	0.6	3
106	Higher Incidence of Graft Rejection in Non-Sibling Fully Matched Related Donor Stem Cell Transplants for Thalassemia Major: A Cautionary Note. <i>Blood</i> , 2018, 132, 2178-2178.	0.6	4
107	Hematological Cancer Consortium: Multi-Center Acute Myeloid Leukemia Registry Data from India. <i>Blood</i> , 2018, 132, 4006-4006.	0.6	4
108	Haplo-Identical Transplants Using Post Transplant Cyclophosphamide (PTCy) Are Associated with Good Outcomes If Transplanted with Early Disease - a Single Centre Analysis from India. <i>Blood</i> , 2018, 132, 4652-4652.	0.6	2

#	ARTICLE	IF	CITATIONS
109	Outcome of Immune Tolerance Induction Using an Extended Half-Life Clotting Factor Concentrate â€” Recombinant Factor VIII Fc (Eloctateâ„¢) â€” a Report from India. <i>Blood</i> , 2018, 132, 2494-2494.	0.6	2
110	Peripheral T cell lymphoma: Clinico-pathological characteristics & outcome from a tertiary care centre in south India. <i>Indian Journal of Medical Research</i> , 2018, 147, 464.	0.4	5
111	Decreased Iron Utilization Leads to Dysregulation of Iron Homeostasis in Aplastic Anemia. <i>Blood</i> , 2018, 132, 3872-3872.	0.6	1
112	Iron Reduction Therapy in Ex-Thalassemics - Long Term Outcome. <i>Blood</i> , 2018, 132, 4591-4591.	0.6	0
113	Communication of Placental Iron Trafficking Proteins with Maternal and Fetal Iron Regulators. <i>Blood</i> , 2018, 132, 3629-3629.	0.6	0
114	Targeted IV Vs Oral Busulfan in Very Young Children with Thalassemia Major Undergoing Matched Allogeneic Haematopoietic Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 5707-5707.	0.6	0
115	Hematological Cancer Consortium: Multi-Center Acute Lymphoblastic Leukemia Registry Data from India. <i>Blood</i> , 2018, 132, 1374-1374.	0.6	0
116	Management of Relapse in Acute Promyelocytic Leukemia Treated with Upfront Arsenic Trioxide Based Regimens. <i>Blood</i> , 2018, 132, 666-666.	0.6	3
117	ATP-binding cassette transporter expression in acute myeloid leukemia: association with<i>in vitro</i> cytotoxicity and prognostic markers. <i>Pharmacogenomics</i> , 2017, 18, 235-244.	0.6	24
118	Generation of an induced pluripotent stem cell line that mimics the disease phenotypes from a patient with Fanconi anemia by conditional complementation. <i>Stem Cell Research</i> , 2017, 20, 54-57.	0.3	9
119	The t(8;14)(q24.1;q32) and its variant translocations: A study of 34 cases. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2017, 10, 126-134.	0.6	8
120	Invasive fungal infection following chemotherapy for acute myeloid leukaemiaâ€”Experience from a developing country. <i>Mycoses</i> , 2017, 60, 686-691.	1.8	26
121	Coexistence of aberrant hematopoietic and stromal elements in myelodysplastic syndromes. <i>Blood Cells, Molecules, and Diseases</i> , 2017, 66, 37-46.	0.6	7
122	Allogeneic stem cell transplantation for thalassemia major in India. <i>Pediatric Hematology Oncology Journal</i> , 2017, 2, 114-120.	0.1	7
123	Long-term outcome following splenectomy for chronic and persistent immune thrombocytopenia (ITP) in adults and children. <i>Annals of Hematology</i> , 2016, 95, 1429-1434.	0.8	56
124	Draft Genome Sequence of Extremely Drug-Resistant <i>Pseudomonas aeruginosa</i> (ST357) Strain CMC_VB_PA_B22862 Isolated from a Community-Acquired Bloodstream Infection. <i>Genome Announcements</i> , 2016, 4, .	0.8	2
125	Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1636-1645.	2.0	71
126	Treatment rates of paediatric acute myeloid leukaemia: a view from three tertiary centres in India â€” response to Gupta <i>et al</i>. <i>British Journal of Haematology</i> , 2016, 175, 347-349.	1.2	3

#	ARTICLE	IF	CITATIONS
127	Role of endovascular embolization in treatment of acute bleeding complications in haemophilia patients. <i>British Journal of Radiology</i> , 2016, 89, 20151064.	1.0	5
128	Population pharmacokinetics of Daunorubicin in adult patients with acute myeloid leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 1051-1058.	1.1	20
129	Broncho-Pericardial Fistula Leading to Pneumopericardium Following Allogeneic Stem Cell Transplantation. <i>Indian Journal of Pediatrics</i> , 2016, 83, 1206-1207.	0.3	1
130	Primary Breast T Cell Lymphoma Involving Nipple-Areolar Complex in a Young Patient. <i>Indian Journal of Surgery</i> , 2016, 78, 499-501.	0.2	0
131	Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 248-257.	2.0	33
132	Clinical, Hematological and Molecular Analysis of Homozygous Hb E (<i>HBB</i> : c.79G>>A) in the Indian Population. <i>Hemoglobin</i> , 2016, 40, 16-19.	0.4	4
133	Leukocyte Adhesion Deficiency-I: Clinical and Molecular Characterization in an Indian Population. <i>Indian Journal of Pediatrics</i> , 2016, 83, 799-804.	0.3	14
134	Atypical <i>BCR-ABL1</i> fusion transcripts in adult B-acute lymphoblastic leukemia, including a novel fusion transcript-e8a1. <i>Leukemia and Lymphoma</i> , 2016, 57, 2481-2484.	0.6	5
135	Comparing Outcomes with Bone Marrow or Peripheral Blood Stem Cells as Graft Source for Matched Sibling Transplants in Severe Aplastic Anemia across Different Economic Regions. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 932-940.	2.0	43
136	Molecular Mechanisms of Colistin Resistance in <i>Klebsiella pneumoniae</i> Causing Bacteremia from India—A First Report. <i>Frontiers in Microbiology</i> , 2016, 7, 2135.	1.5	95
137	Metabolic Rewiring Drives Resistance to Arsenic Trioxide in Acute Promyelocytic Leukemia. <i>Blood</i> , 2016, 128, 3956-3956.	0.6	5
138	Management of Relapsed Acute Promyelocytic Leukemia Post ATO Upfront Therapy: Open-Labelled Phase II Study Evaluating Role of Proteasome Inhibition. <i>Blood</i> , 2016, 128, 446-446.	0.6	1
139	Role of miRNA in Micro-Environment Mediated Drug Resistance in Acute Promyelocytic Leukemia to Arsenic Trioxide. <i>Blood</i> , 2016, 128, 5125-5125.	0.6	1
140	A 5'UTR Polymorphism in <i>NT5E</i> Gene Influences Outcome in Patients with Acute Myeloid Leukemia Undergoing Hematopoietic Stem Cell Transplantation with Fludarabine Based Conditioning Regimen. <i>Blood</i> , 2016, 128, 984-984.	0.6	2
141	Late-onset acute graft-versus-host disease mimicking hand, foot, and mouth disease. <i>Indian Dermatology Online Journal</i> , 2016, 7, 509.	0.2	1
142	Rapidly progressing necrotic ulcerations and sinuses in specific cutaneous Hodgkin's disease. <i>Indian Dermatology Online Journal</i> , 2016, 7, 436.	0.2	0
143	Osteoblast Differentiation of Stromal Cells Induced By Leukemic Cells. <i>Blood</i> , 2016, 128, 5062-5062.	0.6	0
144	Alteration of the Hematopoietic Components, Mesenchymal Stromal Cells and Vascular Elements in the Bone Marrow Niche in Myelodysplastic Syndrome: Refractory Cytopenia with Multilineage Dysplasia. <i>Blood</i> , 2016, 128, 5516-5516.	0.6	0

#	ARTICLE	IF	CITATIONS
145	Fate of Ikaros in Multiple Myeloma Cells upon Treatment with Lenalidomide and Proteasome Inhibitor. <i>Blood</i> , 2016, 128, 3281-3281.	0.6	1
146	Multi-Drug Resistant Organisms Are Common in Fecal Surveillance Cultures and Do Not Predict Bacteremia but Correlate with Poorer Outcomes in Patients Undergoing Allogeneic Stem Cell Transplants. <i>Blood</i> , 2016, 128, 3406-3406.	0.6	0
147	Second Hematopoietic SCT for Thalassemia Major: Improved Clinical Outcomes with a Treosulfan Based Conditioning Regimen. <i>Blood</i> , 2016, 128, 2201-2201.	0.6	0
148	Role of Pre-Transplant Cardiac and Hepatic T2* Magnetic Resonance for Risk Assessment in Patients with Thalassemia Major Undergoing an Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 2200-2200.	0.6	0
149	Characterization of Clinical and Laboratory Profiles of the Deletional β -2-Globin Gene Polyadenylation Signal Sequence (AATAAAGTAAATAA) in an Indian Population. <i>Hemoglobin</i> , 2015, 39, 415-418.	0.6	6
150	Acute myeloid leukaemia: challenges and real world data from India. <i>British Journal of Haematology</i> , 2015, 170, 110-117.	1.2	96
151	Genetic modifiers of secondary iron overload in beta thalassemia major. <i>Blood Cells, Molecules, and Diseases</i> , 2015, 54, 242-243.	0.6	1
152	RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia. <i>Pharmacogenomics</i> , 2015, 16, 877-890.	0.6	41
153	Early T cell precursor lymphoid blast crisis of chronic myeloid leukemia – A novel transformation. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2015, 8, 43-46.	0.6	5
154	Prognostic Significance of Immunophenotypic Composition of B Cell Acute Lymphoblastic Leukemia at Diagnosis: A Novel Immunophenotype Based Risk Score. <i>Blood</i> , 2015, 126, 2620-2620.	0.6	1
155	Population Pharmacokinetics of Fludarabine and Treosulfan in Patients with Thalassemia Undergoing Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 3120-3120.	0.6	6
156	Comparison of Newly Diagnosed and Relapsed Patients with Acute Promyelocytic Leukemia Treated with Arsenic Trioxide: Insight into Mechanisms of Resistance. <i>PLoS ONE</i> , 2015, 10, e0121912.	1.1	43
157	Coagulopathy in Acute Promyelocytic Leukemia: Strategies to Improve Assessment of Hemostatic Risk. <i>Blood</i> , 2015, 126, 3758-3758.	0.6	0
158	Donor Lymphocyte Infusion in Patients with Thalassemia Major Who Have Mixed Chimerism Following Allogeneic Stem Cell Transplant. <i>Blood</i> , 2015, 126, 1965-1965.	0.6	1
159	Generic Intravenous Busulfan in Hematopoietic Stem Cell Transplantation: Relevance of Therapeutic Drug Monitoring. <i>Blood</i> , 2015, 126, 4322-4322.	0.6	1
160	Improved Outcomes with Allogeneic Stem Cell Transplantation for Aplastic Anaemia Using HLA Identical Sibling Donors: The Indian Stem Cell Transplant Registry (ISCTR) Experience. <i>Blood</i> , 2015, 126, 4386-4386.	0.6	1
161	Molecular Basis of Von Willebrand Disease in Patients from India. <i>Blood</i> , 2015, 126, 1102-1102.	0.6	0
162	Efficacy of Second Line Agents Dapsone & Azathioprine in Children & Adults with Immune Thrombocytopenia: Single Centre Experience from India. <i>Blood</i> , 2015, 126, 1064-1064.	0.6	1

#	ARTICLE	IF	CITATIONS
163	Adult Acute Lymphoblastic Leukemia: A Cost Effective Strategy and Limitations of Intensification of Therapy in India. <i>Blood</i> , 2015, 126, 3732-3732.	0.6	0
164	Association of growth differentiation factor 15 (GDF15) polymorphisms with serum GDF15 and ferritin levels in β^2 -thalassemia. <i>Annals of Hematology</i> , 2014, 93, 2093-2095.	0.8	12
165	Diffuse Large B Cell Lymphoma in Wiskott-Aldrich Syndrome: A Case Report and Review of Literature. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2014, 30, 309-313.	0.3	10
166	Clinical and Molecular Characterization of Fanconi Anemia: An Indian Perspective. <i>Blood</i> , 2014, 124, 2938-2938.	0.6	3
167	Population Pharmacokinetics of Daunorubicin in AML: Influence on Clinical Outcome. <i>Blood</i> , 2014, 124, 902-902.	0.6	0
168	Proteasome Activity Is Dispensable for the Degradation of PML-RAR α : Efficacy of Bortezomib Along with Arsenic Trioxide in the Treatment of Arsenic Sensitive and Resistant Acute Promyelocytic Leukemia. <i>Blood</i> , 2014, 124, 3741-3741.	0.6	0
169	The Addition of Meloxicam to G-CSF Is Associated with Good Mobilization Rates, Faster Engraftment and Reduced Toxicity and Hospital Stay after Autologous Stem Cell Transplantation – a Phase II Study. <i>Blood</i> , 2014, 124, 2455-2455.	0.6	0
170	Pre-Transplant Consolidation and Cost Effectiveness of RIC Allogeneic SCT in Patients of AML-CR1 in India. <i>Blood</i> , 2014, 124, 2462-2462.	0.6	0
171	Pharmacokinetics of Fludarabine in Patients with Aplastic Anemia Undergoing Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 3884-3884.	0.6	0
172	The use of a fludarabine-based conditioning regimen in patients with severe aplastic anemia – a retrospective analysis from three Indian centers. <i>Clinical Transplantation</i> , 2013, 27, 923-929.	0.8	19
173	Improved Clinical Outcomes of High Risk β^2 Thalassemia Major Patients Undergoing a HLA Matched Related Allogeneic Stem Cell Transplant with a Treosulfan Based Conditioning Regimen and Peripheral Blood Stem Cell Grafts. <i>PLoS ONE</i> , 2013, 8, e61637.	1.1	78
174	Delay In Onset Of First Transfusion and Increased Risk Of Graft Rejection In β^2 Thalassemia Patients Undergoing a HLA Matched Related Allogeneic Stem Cell Transplant. <i>Blood</i> , 2013, 122, 701-701.	0.6	0
175	Clinical Profile and Outcome Of Patients With Graft Rejection Following Related HLA Matched Allogeneic Stem Cell Transplant For β^2 Thalassemia Major. <i>Blood</i> , 2013, 122, 4546-4546.	0.6	0
176	Pharmacokinetics Of a Generic Formulation Of Intravenous Busulfan (BUCELON 60 μ g) In Patients Undergoing Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2013, 122, 3280-3280.	0.6	0
177	NK Cell Mediated Cytotoxicity Against Malignant Promyelocytes Enhanced By Arsenic Trioxide: Potential Clinical Relevance. <i>Blood</i> , 2013, 122, 1455-1455.	0.6	12
178	A Novel 26 bp Deletion [HBB: c.20_45del26bp] in Exon 1 of the β^2 -Globin Gene Causing β^2 -Thalassemia Major. <i>Hemoglobin</i> , 2012, 36, 98-102.	0.4	5
179	Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy. <i>Blood</i> , 2012, 119, 3413-3419.	0.6	45
180	Polymorphisms in the Immunoregulatory Genes are Associated with Hematopoietic Recovery and Increased Susceptibility to Bacterial Infections in Patients with Thalassemia Major Undergoing Matched Related Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1219-1226.	2.0	6

#	ARTICLE	IF	CITATIONS
181	RNA Expression and Polymorphisms in Imatinib Influx and Efflux Transporters Influence Molecular Response to Imatinib Therapy in Newly Diagnosed Patients with Chronic Myeloid Leukemia.. Blood, 2012, 120, 2785-2785.	0.6	0
182	A Phase II Study Using Post-Transplant Cyclophosphamide (PTC) As Graft Versus Host Disease (GVHD) Prophylaxis in Patients Undergoing HLA Matched Sibling Donor Stem Cell Transplant (SCT) for Severe Aplastic Anemia (SAA). Blood, 2012, 120, 4199-4199.	0.6	0
183	Community Based Evaluation of Prevalence of Inhibitors in Patients with Severe Hemophilia A in India and Their Correlation with Environmental and Genetic Factors. Blood, 2012, 120, 3380-3380.	0.6	0
184	Clinical Profile and Outcomes of Patients with β^2 Thalassemia Major and Hepatitis C Virus Infection Undergoing an Allogeneic Stem Cell Transplant. Blood, 2012, 120, 4160-4160.	0.6	27
185	Mechanism of Synergy Between Bortezomib and Arsenic Trioxide in Acute Promyelocytic Leukemia and Clinical Efficacy in Relapsed Patients. Blood, 2012, 120, 3607-3607.	0.6	0
186	ABC Transporter Expression in Acute Myeloid Leukemia: Association with in Vitro Cytotoxicity and Prognostic Markers. Blood, 2012, 120, 1438-1438.	0.6	0
187	Genetic Diagnosis of Inherited Bleeding Disorders in 1250 Proband From India: A Single Centre Experience. Blood, 2012, 120, 1127-1127.	0.6	0
188	Myeloid Derived Suppressor Cells in Acute Leukemia and Its Association with Conventional Cytogenetic and Molecular Risk Factors. Blood, 2012, 120, 1446-1446.	0.6	2
189	High Expression of p53 and Growth Differentiation Factor-15 in Beta-Thalassemia.. Blood, 2012, 120, 2130-2130.	0.6	0
190	Patterns of Immune Reconstitution in Patients with Acute Promyelocytic Leukemia Treated with Single Agent Arsenic Trioxide and Its Impact On Time to Molecular Remission. Blood, 2012, 120, 3552-3552.	0.6	0
191	Molecular and Functional Characterization of Two Novel Missense Mutations in Iron Transport Protein Causing Hypochromic Microcytic Anemia and Hemosiderosis. Blood, 2012, 120, 3202-3202.	0.6	0
192	Clinical, Cellular and Molecular Differences Between Newly Diagnosed and Relapsed Patients with Acute Promyelocytic Leukemia: Insights Into Mechanisms of Resistance. Blood, 2012, 120, 1390-1390.	0.6	8
193	Comparison of Outcomes after Transplantation of G-CSF α Stimulated Bone Marrow Grafts versus Bone Marrow or Peripheral Blood Grafts from HLA-Matched Sibling Donors for Patients with Severe Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2011, 17, 1018-1024.	2.0	60
194	Pharmacokinetics of Cyclophosphamide Metabolites Influence Outcome in Patients with β^2 -Thalassemia Major Undergoing Allogeneic HSCT. Blood, 2011, 118, 1941-1941.	0.6	1
195	Final Analysis of a Multi-Center Randomized Controlled Trial (IAPLSG04) to Study the Optimal Duration of Arsenic Trioxide Maintenance Therapy in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia. Blood, 2011, 118, 426-426.	0.6	1
196	Results of Allogeneic Hematopoietic Cell Transplantation in Persons with Fanconi Anemia and Pretransplant Cytogenetic Abnormalities, Myelodysplastic Syndrome, or Acute Leukemia. Blood, 2011, 118, 838-838.	0.6	0
197	Response to Immunosuppressive Therapy with Antithymocyte Globulin (ATG) In Older Patients with Aplastic Anemia. Blood, 2011, 118, 4374-4374.	0.6	0
198	Improved Clinical Outcomes of High Risk β^2 Thalassemia Major Patients Under Going a HLA Matched Related Allogeneic Stem Cell Transplant with the Use of a Treosulphan Based Conditioning Regimen and Peripheral Blood Stem Cell Grafts. Blood, 2011, 118, 1017-1017.	0.6	0

#	ARTICLE	IF	CITATIONS
199	Expression of Ara-C Metabolizing Enzymes Mediates in Vitro Sensitivity to Ara-C in Primary AML Cells From Patients with De novo AML. Blood, 2011, 118, 3481-3481.	0.6	0
200	HLA DR15 Antigen Status Does Not Impact Graft-Versus-Host Disease or Disease-Free Survival in HLA-Matched Sibling Transplantation for Hematologic Malignancies. Blood, 2011, 118, 3094-3094.	0.6	0
201	Carbonyl Reductase 1 Expression and Polymorphisms Influence Daunorubicin Metabolism in AML. Blood, 2011, 118, 2484-2484.	0.6	0
202	Rationale and Efficacy of Bortezomib in the Treatment of Acute Promyelocytic Leukemia in Combination with Arsenic Trioxide: In-Vitro and Phase I Data. Blood, 2011, 118, 947-947.	0.6	0
203	Role of Minimal Residual Disease Monitoring in Acute Promyelocytic Leukemia Treated with Arsenic Trioxide in Frontline Therapy. Blood, 2011, 118, 941-941.	0.6	0
204	Single-Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Long-Term Follow-Up Data. Journal of Clinical Oncology, 2010, 28, 3866-3871.	0.8	235
205	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IS SUPERIOR TO IMMUNOSUPPRESSIVE THERAPY IN INDIAN CHILDREN WITH APLASTIC ANEMIA—A SINGLE-CENTER ANALYSIS OF 100 PATIENTS. Pediatric Hematology and Oncology, 2010, 27, 122-131.	0.3	26
206	Trough Level of First Dose of Busulfan (C _{min1}) Is a Stronger Predictor of Graft Rejection Than Steady State Concentration (C _{ss1}) In Patients with Beta Thalassemia Major Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2010, 116, 518-518.	0.6	1
207	Allogeneic Transplant In Children with Severe Aplastic Anemia — Excellent Outcomes with the Use of a Fludarabine Based Conditioning Regimen. Blood, 2010, 116, 3519-3519.	0.6	0
208	Evaluation of Mechanisms of Resistance to Arsenic Trioxide In Patients with Acute Promyelocytic Leukemia. Blood, 2010, 116, 2746-2746.	0.6	0
209	Fludarabine-based reduced intensity conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with aplastic anemia and fungal infections. Clinical Transplantation, 2009, 23, 228-232.	0.8	14
210	Impact of pretransplant splenectomy on patients with β^0 thalassemia major undergoing a matched related allogeneic stem cell transplantation. Pediatric Transplantation, 2009, 13, 171-176.	0.5	18
211	Cellular Immune Reconstitution and Its Impact on Clinical Outcome in Children with β^0 Thalassemia Major Undergoing a Matched Related Myeloablative Allogeneic Bone Marrow Transplant. Biology of Blood and Marrow Transplantation, 2009, 15, 597-609.	2.0	19
212	Comparison of Clinical Outcomes of Patients with Relapsed Acute Promyelocytic Leukemia Induced with Arsenic Trioxide and Consolidated with Either an Autologous Stem Cell Transplant or an Arsenic Trioxide-Based Regimen. Biology of Blood and Marrow Transplantation, 2009, 15, 1479-1484.	2.0	84
213	A Fludarabine Based Conditioning Regimen Associated with A Good Survival Following HLA Identical Sibling/Family Donor Transplants in Patients with Aplastic Anemia. Blood, 2009, 114, 1194-1194.	0.6	1
214	Single Agent Arsenic Trioxide Regimen for the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Initial Results of a Multicenter Randomized Controlled Study From India to Study the Optimal Duration of Arsenic Trioxide Maintenance Therapy (IAPLSG04). Blood, 2009, 114, 2082-2082.	0.6	2
215	Risk Stratification without a Liver Biopsy of Patients with β^0 Thalassemia Major Undergoing a Matched Related Allogeneic Bone Marrow Transplant. Blood, 2009, 114, 659-659.	0.6	11
216	Polymorphisms in the CYP450 Genes Influences Regimen Related Toxicity and Outcome in Patients with Beta Thalassemia Major Undergoing HSCT. Blood, 2009, 114, 869-869.	0.6	2

#	ARTICLE	IF	CITATIONS
217	Population Pharmacokinetics of Busulfan in Patients with Beta Thalassaemia Major Undergoing HSCT Reveals Body Weight, GSTA1 and CYP3A4 Promoter Polymorphisms as Main Covariates Explaining the Inter-Individual Variation.. Blood, 2009, 114, 3349-3349.	0.6	0
218	Comparison of Differential Gene Expression Profiles of Relapsed Patients with Acute Promyelocytic Leukemia Treated with Arsenic Trioxide with the Profile of An Arsenic Trioxide Resistant NB4 Cell Line.. Blood, 2009, 114, 3460-3460.	0.6	0
219	Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Long Term Follow-up Data.. Blood, 2009, 114, 846-846.	0.6	0
220	Fludarabine based reduced intensity conditioning regimens in children undergoing allogeneic stem cell transplantation for severe aplastic anemia. Pediatric Transplantation, 2008, 12, 14-19.	0.5	32
221	Minimal Residual Disease Monitoring in Patients with Newly Diagnosed Acute Promyelocytic Leukemia Treated with Arsenic Trioxide. Blood, 2008, 112, 2534-2534.	0.6	0
222	Increased ABCG2 Expression Could Be Responsible for Resistance to Imatinib Mesylate in Patients with Chronic Myeloid Leukemia Who Do Not Have Mutations in BCR-ABL Kinase Domain. Blood, 2008, 112, 5026-5026.	0.6	53
223	Endonography findings in brunneroma. Indian Journal of Gastroenterology, 2008, 27, 45.	0.7	1
224	A New Stratification Strategy That Identifies a Subset of Class III Patients with an Adverse Prognosis among Children with β^2 Thalassemia Major Undergoing a Matched Related Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2007, 13, 889-894.	2.0	67
225	Fludarabine and cyclophosphamide based reduced intensity conditioning (RIC) regimens reduce rejection and improve outcome in Indian patients undergoing allogeneic stem cell transplantation for severe aplastic anemia. Bone Marrow Transplantation, 2007, 40, 13-18.	1.3	57
226	Bone Marrow Transplantation for β^2 Thalassemia Major: Long Term Experience from a Single Centre in India.. Blood, 2007, 110, 1106-1106.	0.6	1
227	Reduced Intensity Conditioning (RIC) with Fludarabine, Busulfan and Cyclophosphamide for High Risk Patients with Thalassemia Major Undergoing Allogeneic Bone Marrow Transplantation Results in High Rejection Rates.. Blood, 2007, 110, 1998-1998.	0.6	2
228	Pharmacokinetic and Pharmacodynamic Evaluation of a Biosimilar Rituximab in Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP (Rituximab, Cyclophosphamide, Adriamycin,) Tj ETQq0.6 0 rgBT/Overlock	0.6	0
229	Fludarabine and Melphalan Conditioning Regimen in Young Patients with Acute Myeloid Leukemia in CR1 Undergoing a Matched Related Allogeneic Stem Cell Transplant: A Single Center Experience.. Blood, 2007, 110, 5049-5049.	0.6	1
230	Treatment of Relapsed and Refractory Acute Myeloid Leukemia with a Salvage FLAG-IDA Chemotherapy Regimen Followed by a HLA Matched Related Allogeneic PBSC Infusion without Additional Conditioning.. Blood, 2007, 110, 5050-5050.	0.6	1
231	Analysis of β^2 Globin Mutations in the Indian Population: Presence of Rare and Novel Mutations and Region Wise Heterogeneity.. Blood, 2007, 110, 3822-3822.	0.6	0
232	G-CSF Primed Bone Marrow Is Not Superior to Unprimed Bone Marrow as a Source of Stem Cells in HLA Matched Related Allogeneic SCT for β^2 Thalassemia Major.. Blood, 2007, 110, 5052-5052.	0.6	0
233	Polymorphism in the IFN- γ Gene Is Associated with Severe Acute Graft Versus Host Disease in β^2 Thalassemia Major Patients Undergoing Matched Related Hematopoietic Stem Cell Transplantation (HSCT).. Blood, 2007, 110, 1105-1105.	0.6	3
234	Molecular Analysis of WASP Gene - First Report from India.. Blood, 2007, 110, 3217-3217.	0.6	0

#	ARTICLE	IF	CITATIONS
235	Comparison of Clinical Outcomes of Relapsed APL Patients Induced with ATO and Consolidated with Either an Autologous SCT or ATO Based Treatment Regimen.. Blood, 2007, 110, 2880-2880.	0.6	7
236	Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood, 2006, 107, 2627-2632.	0.6	313
237	Infections in children undergoing allogeneic bone marrow transplantation in India. Pediatric Transplantation, 2006, 10, 48-54.	0.5	34
238	Dendritic Cell Type 2 Counts on Day 28 in HLA-Matched Related Allogeneic PBSCT Predicts the Incidence of Acute and Chronic GVHD.. Blood, 2006, 108, 2893-2893.	0.6	8
239	A Low Intensity Protocol of Fludarabine, Busulfan and Cyclophosphamide Reduces Toxicity without Compromising Engraftment in Children Undergoing Allogeneic Bone Marrow Transplantation for Beta Thalassemia Major.. Blood, 2006, 108, 5366-5366.	0.6	0
240	Two Mutations (1717 T→C, GP IX;124del145, GPIb beta) Occur Frequently among Patients with Bernard Soulier Syndrome in India.. Blood, 2006, 108, 1096-1096.	0.6	0
241	IL-10 Polymorphism and TGF-β ² Haplotypes Are Associated with Rejection of Graft in Children with Beta Thalassemia Major Undergoing Matched Related Bone Marrow Transplantation (BMT).. Blood, 2006, 108, 3011-3011.	0.6	0
242	Impact of Additional Cytogenetic Changes and FLT3 Mutations on the Outcome of Patients with Newly Diagnosed Acute Promyelocytic Leukaemia Treated with Single Agent Arsenic Trioxide.. Blood, 2006, 108, 2346-2346.	0.6	0
243	A New Stratification Strategy That Identifies a Subset of Class III Patients among Children with β ² Thalassemia Major Undergoing a Matched Related Allogeneic Stem Cell Transplantation.. Blood, 2006, 108, 2996-2996.	0.6	0
244	Dapsone for chronic idiopathic thrombocytopenic purpura in children and adults - a report on 90 patients. European Journal of Haematology, 2005, 75, 328-331.	1.1	57
245	Hematological and molecular remission with combination chemotherapy in a patient with PLZF-RAR [±] acute promyelocytic leukemia (APML). Annals of Hematology, 2005, 84, 406-408.	0.8	5
246	Developing an Algorithm for Monitoring Chimerism after Allogeneic Bone Marrow Transplantation - A Single Centre Experience.. Blood, 2005, 106, 5301-5301.	0.6	0
247	Durable Remissions with Single Agent As ₂ O ₃ in the Treatment of Newly Diagnosed Cases of Acute Promyelocytic Leukemia: Risk Stratification within This Group and Potential Impact on Future Algorithms.. Blood, 2005, 106, 892-892.	0.6	0
248	Surveyor ^h , ^Δ Nuclease: A New Rapid and Effective Strategy for Detection of Single Nucleotide Changes in Alpha Globin Genes.. Blood, 2005, 106, 3653-3653.	0.6	0
249	A Pilot Study of Rabbit Antithymocyte Globulin - TECELAC Combined with Cyclosporine and Prednisolone as Immunosuppressive Therapy for Severe Aplastic Anemia.. Blood, 2005, 106, 3749-3749.	0.6	0
250	Oral Prednisolone Produces a Durable Response in Pediatric Myelodysplastic Syndromes (MDS).. Blood, 2005, 106, 4906-4906.	0.6	0
251	The Role of Donor Lymphocyte Infusion (DLI) and Imatinib Mesylate in the Treatment of Relapse after Allogenic Stem Cell Transplant for Chronic Myeloid Leukemia.. Blood, 2005, 106, 5393-5393.	0.6	0
252	Fludarabine Based Conditioning for Allogeneic Transplantation in Severe Aplastic Anemia.. Blood, 2005, 106, 2029-2029.	0.6	0

#	ARTICLE	IF	CITATIONS
253	Infections among allogeneic bone marrow transplant recipients in India. Bone Marrow Transplantation, 2004, 33, 311-315.	1.3	61
254	Arsenic Trioxide (As ₂ O ₃) in the Treatment of Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APML) - Toxicity and Outcome.. Blood, 2004, 104, 889-889.	0.6	21
255	Six Novel Mutations Including Triple Heterozygosity for Phe31Ser, 514delT and 516T→C Mutations in Factor X Gene Is Responsible for Congenital Factor X Deficiency in Patients of Indian and Nepali Origin.. Blood, 2004, 104, 1042-1042.	0.6	6
256	Pharmacogenetics of Cyclophosphamide in Patients with Beta Thalassemia Major Undergoing Bone Marrow Transplantation.. Blood, 2004, 104, 99-99.	0.6	0
257	Molecular Genetics of Hereditary Prothrombin Deficiency in Indian Patients: Identification of a Novel Ala362→Thr (Prothrombin Vellore 1) Mutation by Conformation Sensitive Gel Electrophoresis.. Blood, 2004, 104, 1037-1037.	0.6	0
258	Cyclophosphamide Kinetics Influences Toxicity and Outcome of Bone Marrow Transplantation in Patients with β^2 -Thalassemia Major.. Blood, 2004, 104, 1820-1820.	0.6	0
259	Polymyositis - an unusual manifestation of chronic graft-versus-host disease. Rheumatology International, 2001, 20, 169-170.	1.5	20
260	Cyclophosphamide induced haemorrhagic myocarditis-pericarditis: a rare but lethal complication in the setting of allogeneic stem cell transplantation. Bone Marrow Transplantation, 0, , .	1.3	1